Joseph M Luettgen Selected Research

Factor XIa (Coagulation Factor XIa)

1/2022	Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
1/2020	Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.
1/2020	Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
2/2014	Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph M Luettgen Research Topics

Disease

14	Thrombosis (Thrombus) 01/2022 - 12/2003
8	Hemorrhage 01/2020 - 03/2010
1	Stroke (Strokes) 02/2003
1	Infarction (Infarctions) 02/2003
1	Cerebral Hemorrhage 02/2003

Drug/Important Bio-Agent (IBA)

4	Factor XIa (Coagulation Factor XIa)IBA 01/2022 - 02/2014
4	AnticoagulantsIBA 01/2020 - 03/2010
4	Factor VIIa (Activated Factor VII)IBA 01/2017 - 02/2014
3	Thromboplastin (Tissue Factor)IBA 11/2016 - 08/2010
3	apixabanIBA 09/2011 - 05/2008
3	Factor Xa (Coagulation Factor Xa)IBA 09/2011 - 02/2003
2	EnzymesIBA 01/2022 - 01/2020
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2020 - 02/2014
2	Thrombin FDA Link 08/2010 - 03/2010
2	Peptide Hydrolases (Proteases)FDA Link 03/2010 - 08/2006
2	Blood Coagulation Factors (Coagulation Factor)IBA 03/2010 - 08/2006
1	milvexianIBA 01/2022
1	pyridineIBA 01/2020
1	BMS-962212IBA 01/2018
1	Serine Proteases (Serine Protease)IBA 12/2016
1	compound 21IBA 01/2016
1	BMS 593214IBA 04/2013
1	anthranilamideIBA 05/2008
1	DPC 602IBA 02/2003
1	Hemoglobins (Hemoglobin)IBA 02/2003

Therapy/Procedure

2	Therapeutics 01/2020 - 03/2010
1	Intravenous Administration 12/2017
1	Lasers (Laser) 02/2003